JOHNSTON STEVEN C.,KRAWIEC MARIUSZ,ZAMAN NOREEN TASNEEM,KESHAVARZ-SHOKRI ALI,ZLOKARNIK GREGOR,ALARGOVA ROSSITZA GUEORGUIEVA,AREKAR SNEHA G.,ZHANG YUEGANG,VAN GOOR FREDRICK F.,MEDEK ALES,ALCACIO TIM ED
申请号：
NZ60304211
公开号：
NZ603042A
申请日:
2011.04.22
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed is a pharmaceutical composition comprising: Compound 1 SDD Formulation and VX-661 in Amorphous Form, wherein: Compound 1 SDD Formulation is a spray dried dispersion of ivacaftor (VX-770), which comprises from about 45 wt% to about 85 wt% of substantially amorphous ivacaftor by weight of the dispersion, from about 14.45 wt% to about 55.55 wt% of hydroxypropylmethylcellulose acetate succinate (HPMCAS) by weight of the dispersion, and from about 0.45 wt% to about 0.55 wt% sodium lauryl sulfate (SLS) by weight of the dispersion. Also disclosed is the use of the pharmaceutical composition as defined above in the manufacture of a medicament for treating a CFTR mediated disease in a human, wherein the CFTR mediated disease is selected from cystic fibrosis, COPD, emphysema, dry-eye disease or osteoporosis.
